Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2CNS 1

Conditions

Neoplasms 2Glioblastoma 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × CT-322 × Clear all
NCT01146171 2012-02-07

Japanese Phase 1 Study of BMS-844203 (CT322)

Bristol-Myers Squibb

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00768911 2010-10-27

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Unknown
30 enrolled
CNS

Glioblastoma

NCT00374179 2009-02-24

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡